JEMPERLI (dostarlimab-gxly) + CP: The first and only* FDA-approved IO combination with statistically significant OS benefit in primary advanced or recurrent EC1-6

* All-comers (overall population) OS analysis: HR=0.69, 95% CI: 0.54-0.89, P=0.002; HR based on stratified Cox regression model and one-sided P-value based on stratified log-rank test was statistically significant. Median OS with JEMPERLI + CP was 44.6 months (95% CI: 32.6-NR) vs 28.2 months (95% CI: 22.1-35.6) with CP alone.1

RUBY Part 1: A phase 3, randomized, double-blind, placebo-controlled trial of patients with primary advanced or recurrent EC (N=494, all-comers) who were randomized 1:1 to JEMPERLI + CP or placebo + CP Q3W for 6 cycles, followed by JEMPERLI or placebo Q6W, respectively, until disease progression, unacceptable toxicity, or up to 3 years. Major efficacy endpoints were investigator-assessed PFS by RECIST v1.1 in the dMMR/MSI-H and all-comers populations, and OS in all-comers.1

Explore the data and safety profile of JEMPERLI in 3 indications:

Pink Endometrial Cancer Icon

1L Primary Advanced or
Recurrent Endometrial Cancer

SEE EFFICACY & SAFETY DATA

Purple Endometrial Cancer Icon

2L dMMR Recurrent or
Advanced Endometrial Cancer

SEE EFFICACY & SAFETY DATA

Solid Tumor Icon

2L dMMR Recurrent or
Advanced Solid Tumors

SEE EFFICACY & SAFETY DATA

1L=first-line; 2L=second-line; CI=confidence interval; CP=carboplatin-paclitaxel; dMMR=mismatch repair deficient; EC=endometrial cancer; HR=hazard ratio; IO=immuno-oncology; IV=intravenous; MSI-H=microsatellite instability-high; OS=overall survival; PFS=progression-free survival; Q3W=every 3 weeks; Q6W=every 6 weeks; RECIST=Response Evaluation Criteria in Solid Tumors v1.1; ST=solid tumors.